Acumen Pharmaceuticals (ABOS) Short term Debt (2025 - 2026)

Acumen Pharmaceuticals (ABOS) reported Short term Debt of $14.1 million for Q1 2026, up 61.13% sequentially from $8.8 million in Q4 2025.

Acumen Pharmaceuticals (ABOS) Short term Debt (2025 - 2026) Analysis & Trends

Acumen Pharmaceuticals (ABOS) has 2 years of Short term Debt data on file, last reported at $14.1 million in Q1 2026.

For the quarter ending Q1 2026, Short term Debt changed N/A year-over-year to $14.1 million; the trailing twelve-month figure through Mar 2026 stood at $14.1 million (changed N/A YoY), and the FY2025 full-year result was $8.8 million, changed N/A from the prior year.
Short term Debt grew to $14.1 million in Q1 2026, from $8.8 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $14.1 million in Q1 2026 to a low of $3.6 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,102.16 Bn	67,101.87 Bn	-
2	Nanobiotix	1,909.44 Bn	1,909.38 Bn	-
3	Akari Therapeutics	989.71 Bn	989.71 Bn	-
4	BeOne Medicines	471.58 Bn	466.79 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.97 Bn	114.72 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.93 Bn	61.18 Bn	3.31 Bn
7	Belite Bio	62.68 Bn	62.68 Bn	-
8	Argenx Se	55.80 Bn	50.61 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.37 Bn	34.36 Bn	959.66 Mn
10	Acumen Pharmaceuticals	140.98 Mn	140.98 Mn	-

Download Data